Author

Nathan Chan

Broad Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Neuroscience· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Assay:CRISPR screen· 1 Organism:non-human primate· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Eric Vallabh MinikeliD· 3 shared Kendrick DeSouza-Lenz· 3 shared Michael Howard· 3 shared Sonia M. VallabhiD· 3 shared Taylor L CorridoniD· 3 shared Vanessa LaversenneiD· 3 shared Alissa A. CoffeyiD· 2 shared Daniel A. SpragueiD· 2 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersNeuroscience

Eric Vallabh MinikelORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Prevention of prion disease symptoms in mice with deep PrP lowering

Juliana E Gentile, Jonathan E. Farley, Margaret N. Kelemen, Meredith A Mortberg, Taylor L Corridon, Vanessa Laversenne, Jessica R Bombardier, Carlos Umaña, Kendrick DeSouza-Lenz, Michael Howard, Kenia Guzman, Nathan Chan, Daniel A. Sprague, Alissa A. Coffey, Jordyn Trapilo, , Eric Vallabh Minikel

This study demonstrates that deep PrP lowering with a potent siRNA prevents prion disease symptoms in mice and extends survival in symptomatic animals.

bioRxiv · Oct 24, 2026 · PreprintNeuroscience

PrP turnover in vivo and the time to effect of prion disease therapeutics

Taylor L Corridon, Jill O’Moore, Alyssa Seerley, Daniel A. Sprague, Yuan Lian, Vanessa Laversenne, Briana Noble, Nikita G Kamath, Fiona E. Serack, Abdul Basit Shaikh, Brian Erickson, Craig R. Braun, Kendrick DeSouza-Lenz, Michael Howard, Nathan Chan, , Eric Vallabh Minikel

The paper measures PrP half-life in vivo and shows it limits the time to effect of PrP-lowering therapies, with implications for drug development and clinical trial design.

PLoS Pathogens · May 26, 2026Peer-reviewedNeuroscience

Divalent siRNA for prion disease

Juliana E Gentile, Taylor L Corridon, Fiona E. Serack, Dimas Echeverria, Zachary Kennedy, Corrie L. Gallant‐Behm, Matthew R. Hassler, Garth A. Kinberger, Margaret N Kelemen, Nikita G Kamath, Yuan Lian, Katherine Y. Gross, Rachael Miller, Kendrick DeSouza-Lenz, Michael Howard, , Sonia M. Vallabh

Divalent siRNA 2439-s4 lowers human PrP to 17% residual in transgenic mouse brain after one dose, and a separate mouse Prnp-targeting siRNA extends survival in prion-infected mice.

Nucleic Acids Research · Mar 19, 2026Peer-reviewedNeuroscience✦ In-depth digest